Seoul, South Korea – June 2, 2026 – PSI CRO AG, a global Swiss-based clinical research organization (CRO), is pleased to announce the appointment of Misoon Seo as Country Manager of PSI Korea, strengthening the company’s leadership as demand for its services in South Korea continues to grow.
Korea plays an important role in global development programs, recognized for its experienced investigators, high regulatory standards, and strong ethical framework. Since 2017, PSI has established a strong operational presence in South Korea, with the country emerging as a key contributor to global pivotal trials. In 2024, the company further expanded its footprint by relocating its office to Lotte Tower in Seoul.
With more than 25 years of experience across global pharmaceutical companies and international CROs, Misoon brings a practical, hands-on approach to scaling country operations and delivering complex projects in demanding environments. The appointment of Misoon positions PSI Korea to accelerate its operations with focus, discipline, and a clear objective: helping sponsors bring innovative therapies to patients on time, with confidence and consistency.
I’m delighted to join PSI Seoul and lead the team as we scale our operations in Korea. PSI has built a strong reputation for its unique delivery model across some of the most complex therapeutic areas. Reputation is paramount in Korea, and I look forward to working with our talented team and partners to further strengthen our presence to deliver pivotal clinical trials for our clients.
PSI’s continued growth in Korea follows recent expansions in Asia-Pacific, including Japan, China, Taiwan, India, Singapore, Malaysia, Australia, and New Zealand, where PSI employs dedicated full-time staff.
About PSI
PSI CRO is a global full-service contract research organization (CRO), committed to being the best CRO in the world as measured by its employees, customers, investigators, and vendors. PSI’s key operational differentiator is predictable on-time delivery of clinical trials. This metric remained above 90% in 2025.
The company specializes in pivotal phase 2 and phase 3 clinical trials in oncology, hematology, gastroenterology, immunology, infectious diseases, neuroscience, and other indications. PSI provides expertise in complex trials at the forefront of precision medicine, including platform and umbrella designs, trials in targeted immunotherapy, radiopharmaceuticals, and cell and gene therapies.
In 2025, PSI celebrated its 30th year of business as the only fully independent and privately owned mid-sized CRO. PSI employs over 3,300 people across 58 countries as of March 31st, 2026.
Global headquarters are in Switzerland at 113a Baarerstrasse, Zug 6300.
For more information, visit www.psi-cro.com.
For Media Inquiries
Laura Lange
